The National Horseracing Authority (NHA) and the Onderstepoort Biological Products (OBP) held a meeting to discuss the availability of African Horse Sickness (AHS) vaccine.
The NHA, representing several stakeholders from the equine industry, expressed concerns over the insufficient and irregular production of AHS vaccines over the past four years, which has had a significant impact on the racing industry.
It was emphasised that horses should be adequately vaccinated as mandated by legislation and the Rules of the NHA between 1 June and 31 October annually.
Vaccination coverage of at least 60% of the equine population, estimated at 300 000, was proposed by the NHA as a target to achieve adequate herd immunity and ensure optimal health and welfare of the broader equine population.
The OBP acknowledged that whilst there were challenges in the past, there was improvement in the production and the availability of the AHS vaccine.
The OBP indicated that it would be able to supply the doses proposed by the NHA in the current financial year.
The parties noted that the forecast looks good for improved vaccine production in 2025 as a result of the arrival of the freeze-dryer that the organisation has procured.
It was agreed that a follow-up meeting between the CEO of the OBP and the NHA’s Chief Executive would be scheduled to discuss AHS vaccine distribution.
- Media release by the NHA on Friday, 11 October 2024.
